Review finds promising but variable CBD evidence in dogs and cats
Cannabidiol in small animal practice: current evidence, clinical applications and practical recommendations for dogs and cats.
AI Summary
This mini-review asks what clinical evidence supports cannabidiol (CBD) use in dogs and cats, and summarizes reported effects, safety concerns, and practical considerations. It describes evidence as strongest for canine osteoarthritis and epilepsy: studies suggest CBD may improve pain and mobility in dogs and reduce seizure frequency in refractory epilepsy, but results vary. The abstract provides no sample sizes, effect estimates, or other quantitative results, so the size of any benefit cannot be assessed here.
Evidence for anxiety-related effects appears more consistent for chronic stress than for acute fear. In cats, clinical data remain limited, with preliminary work covering several conditions and safety-related questions. Reported adverse effects include gastrointestinal disturbances and sedation; increases in serum alkaline phosphatase have also been reported in dogs, with uncertain clinical significance. The review supports cautious, selective use as an adjunct rather than a primary therapy, while noting possible drug interactions. This is an abstract-based summary: the review cannot establish optimal dosing, long-term safety, or definitive treatment efficacy, and calls for standardized clinical trials.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.